Tolnaftate

These indications are based on manufacturer information for both originator and generic products. For product specific registered indications, please refer to product specific manufacturer information

Registered South African indications:

• Tinea pedis, tinea cruris, tinea corporis, tinea barbae and tinea manum, due to infections of Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum  audouinii, Epidermophyton floccosum and for pityriasis (tinea) versicolor due to Pityrosporum obiculare

Contraindications

• Hypersensitivity to the active ingredient or any of its excipients

Cautions

• Pregnancy
• Breastfeeding
• Renal impairment
• Hepatic impairment
• Children < 2 years
• Contact with eyes or mucous membranes

Forms avail. in SA and covered in this monograph: cre

Infections caused by: Fungi (including Trichophyton spp., Microsporum spp., Epidermophyton floccosum, Pityrosporum obiculare)

Specific doses based on individual indications

Please note that the dosages below should be used in combination with regional guidelines, taking into account local antibiotic sensitivities

Tinea capitis
Tinea pedis
Tinea cruris
Tinea corporis
Tinea barbae
Tinea manum
Pityriasis versicolor

• Topical (cre): Apply small quantity to affected area(s), 12hrly; Treatment duration: 2-3 weeks

Prolonged treatment of 4-6 weeks may be required if thickening of the skin has occurred

Paed. forms avail. in SA and covered in this monograph: cre 

Infections caused by: Fungi (including Trichophyton spp., Microsporum spp., Epidermophyton floccosum, Pityrosporum obiculare)

Specific doses based on individual indications

Please note that the dosages below should be used in combination with regional guidelines, taking into account local antibiotic sensitivities

Tinea capitis
Tinea pedis
Tinea cruris
Tinea corporis
Tinea barbae
Tinea manum
Pityriasis versicolor

Younger than 2 years

• Not established for use

Older than 2 years

• See adult dosage

Pregnancy 

• Caution; not recommended
• Safety in pregnancy has not been established. However, no teratogenic effects have been observed in clinical use
• In studies in rats and mice, tolnaftate did not exert a deleterious effect on foetal or postnatal development

Breastfeeding

• Caution; not recommended
• It is not known whether topical tolnaftate is secreted into breast milk. However, no undesirable effects in breastfed infants whose mothers were using tolnaftate have been reported

Renal Impairment

• Caution; no information available

Hepatic Impairment

• Caution; no information available

Elderly

• No dose adjustment recommended

Porphyria Information

• Not yet classified (NC)

Skin and Subcutaneous Tissue Disorders

• Contact dermatitis
• Pruritus
• Stinging of skin
• Skin irritation

No information available

None routine

The exact mechanism of action of tolnaftate is unknown. It is thought to distort hyphae and stunt mycelial growth in susceptible fungi.

Spectrum of activity: Fungi (including Trichophyton spp., Microsporum spp., Epidermophyton floccosum, Pityrosporum obiculare)

Tolnaftate is available in several formulations. Please note the list below gives examples of products which are available and is not necessarily comprehensive. The listing of a product does not constitute endorsement of the product by EMGuidance; likewise, failure to list a product does not imply that EMGuidance disapproves of the product. This information is put together on the basis of the National Government's Medicines Price Registry at the time of publication

Cream (per g) 10mg

• Tinaderm (Schering-Plough)